Cargando…

Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports

PURPOSE: To summarize the characteristics and the relevant factors and to give references for preventing adverse drug reactions (ADRs) associated with xiyanping (XYP), we provide a systematic review of adverse case reports about XYP. METHODS: Seven medical databases were searched from inception to J...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shiqi, Kwong, Joey S. W., Zheng, Rui, Wang, Yanping, Shang, Hongcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276469/
https://www.ncbi.nlm.nih.gov/pubmed/30581483
http://dx.doi.org/10.1155/2018/4013912
_version_ 1783378018689875968
author Chen, Shiqi
Kwong, Joey S. W.
Zheng, Rui
Wang, Yanping
Shang, Hongcai
author_facet Chen, Shiqi
Kwong, Joey S. W.
Zheng, Rui
Wang, Yanping
Shang, Hongcai
author_sort Chen, Shiqi
collection PubMed
description PURPOSE: To summarize the characteristics and the relevant factors and to give references for preventing adverse drug reactions (ADRs) associated with xiyanping (XYP), we provide a systematic review of adverse case reports about XYP. METHODS: Seven medical databases were searched from inception to January 2018. Case reports detailing ADRs associated with XYP were included. Data were extracted independently by two reviewers. After the assessment of causality and severity, we carried out a descriptive analysis for the relevant ADRs. RESULTS: Forty-three articles involving a total number of 55 cases were included. Eight cases were off-label drug use. In the remaining 47 cases, 26 (55.3%) had probable causality and 23 (48.9%) were serious cases. XYP used in children (≤14 years old) accounted for 66.0%. Respiratory diseases (83.0%) were major primary diseases. No allergic history mentioned (55.3%) and unspecific drug combination (59.6%) were common in these reports. As for ADR types, anaphylaxis and anaphylactic shock were up to 97.9%. ADRs happened mostly when applying XYP within 30 minutes (70.2%) and the majority (95.7%) were cured when treated in time. CONCLUSIONS: Clinicians and patients are supposed to obey the package insert of XYP in clinical application. Through the results of XYP, normalization of ADR reports is also worthy of attention. High-quality researches are required to improve the drug instruction and evaluate the safety of XYP in effective diseases and different age groups. Mechanism of ADRs aiming at the hypersensitivity and the drug combination should still be further identified.
format Online
Article
Text
id pubmed-6276469
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62764692018-12-23 Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports Chen, Shiqi Kwong, Joey S. W. Zheng, Rui Wang, Yanping Shang, Hongcai Evid Based Complement Alternat Med Review Article PURPOSE: To summarize the characteristics and the relevant factors and to give references for preventing adverse drug reactions (ADRs) associated with xiyanping (XYP), we provide a systematic review of adverse case reports about XYP. METHODS: Seven medical databases were searched from inception to January 2018. Case reports detailing ADRs associated with XYP were included. Data were extracted independently by two reviewers. After the assessment of causality and severity, we carried out a descriptive analysis for the relevant ADRs. RESULTS: Forty-three articles involving a total number of 55 cases were included. Eight cases were off-label drug use. In the remaining 47 cases, 26 (55.3%) had probable causality and 23 (48.9%) were serious cases. XYP used in children (≤14 years old) accounted for 66.0%. Respiratory diseases (83.0%) were major primary diseases. No allergic history mentioned (55.3%) and unspecific drug combination (59.6%) were common in these reports. As for ADR types, anaphylaxis and anaphylactic shock were up to 97.9%. ADRs happened mostly when applying XYP within 30 minutes (70.2%) and the majority (95.7%) were cured when treated in time. CONCLUSIONS: Clinicians and patients are supposed to obey the package insert of XYP in clinical application. Through the results of XYP, normalization of ADR reports is also worthy of attention. High-quality researches are required to improve the drug instruction and evaluate the safety of XYP in effective diseases and different age groups. Mechanism of ADRs aiming at the hypersensitivity and the drug combination should still be further identified. Hindawi 2018-11-15 /pmc/articles/PMC6276469/ /pubmed/30581483 http://dx.doi.org/10.1155/2018/4013912 Text en Copyright © 2018 Shiqi Chen et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chen, Shiqi
Kwong, Joey S. W.
Zheng, Rui
Wang, Yanping
Shang, Hongcai
Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title_full Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title_fullStr Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title_full_unstemmed Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title_short Normative Application of Xiyanping Injection: A Systematic Review of Adverse Case Reports
title_sort normative application of xiyanping injection: a systematic review of adverse case reports
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276469/
https://www.ncbi.nlm.nih.gov/pubmed/30581483
http://dx.doi.org/10.1155/2018/4013912
work_keys_str_mv AT chenshiqi normativeapplicationofxiyanpinginjectionasystematicreviewofadversecasereports
AT kwongjoeysw normativeapplicationofxiyanpinginjectionasystematicreviewofadversecasereports
AT zhengrui normativeapplicationofxiyanpinginjectionasystematicreviewofadversecasereports
AT wangyanping normativeapplicationofxiyanpinginjectionasystematicreviewofadversecasereports
AT shanghongcai normativeapplicationofxiyanpinginjectionasystematicreviewofadversecasereports